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Circulating microRNAs (miRNAs) have been linked to chronic kidney disease. Little is 59 
known about the association between circulating miRNAs and kidney function in patients at 60 
high cardiovascular risk. We therefore investigated the association between a huge panel of 61 
candidate miRNAs and kidney function, based on estimated glomerular filtration rate (eGFR), 62 
in two independent cohorts of patients undergoing coronary angiography. The present study 63 
totally included 438 coronary angiography patients, who were divided into a discovery cohort 64 
(n=120) and a validation cohort (n=318). A candidate miRNA panel comprising 50 renal 65 
miRNAs were selected from the literature and expression levels of circulating miRNAs were 66 
determined by real-time PCR. Out of initially tested candidate-miRNAs, 38 were sufficiently 67 
detectable in plasma. Their association with kidney function was evaluated in the discovery 68 
cohort. Associations of seven out of these miRNAs with eGFR were significant after multiple 69 
testing correction via false discovery rate (FDR) estimation. To verify obtained results, 70 
miRNAs with significant FDR were further analysed in the validation cohort. MiRNAs miR-71 
106b-5p, miR-16-5p, miR-19b-3p, miR-20a-5p, miR-25-3p, and miR-451a proved to be 72 
significantly associated with eGFR also in the validation cohort (all p-values <0.001). 73 
Association between identified renal miRNAs and kidney function was confirmed by 74 
ANCOVA adjusting for age, gender, type 2 diabetes, hypertension, and albumin-to-creatinine 75 
ratio. In conclusion, our study showed that miR-16-5p, miR-19b-3p, miR-20a-5p, miR-25-3p, 76 
miR-106b-5p, and miR-451a are significantly linked to kidney function in coronary 77 
angiography patients. 78 
 79 
  80 





Chronic kidney disease (CKD) is increasing worldwide and is strongly linked to an elevated 83 
risk of cardiovascular and all-cause mortality (31, 36). CKD is characterized by a progressive 84 
loss of kidney function over months or years typically showing a long latent period when the 85 
disease is clinically silent (18). Therefore, early detection of reduced kidney function is 86 
essential to improve risk prediction, particularly in high-risk patients. 87 
 88 
Recently, circulating microRNAs (miRNAs) have emerged as novel diagnostic biomarkers in 89 
many diseases including kidney disease (20, 21). MiRNAs are small non-coding RNAs of 90 
approximately 22 nucleotides in length that usually function as repressors of target genes by 91 
either inhibiting translation or promoting degradation of mRNA (5, 30). Currently, 92 
approximately 2700 mature miRNAs have been identified in humans according to database 93 
miRbase, release 22.1 (15). Many of them are expressed in a tissue and/or cell-specific 94 
manner playing important regulatory roles in virtually all cellular processes inclusive of 95 
kidney development and function (1, 37). Notably, miRNAs can also be detected outside 96 
cells, including circulating cell-free body fluids such as plasma, serum, or urine in a 97 
remarkably stable form (41). It is hypothesized that miRNAs are not only passively released 98 
by necrotic or injured cells but are actively secreted in membrane-bound vesicles (exosomes, 99 
microvesicles) (9, 13), in apoptotic bodies (42), or in vesicle-free but protein-protected 100 
protein-miRNA complexes (3). These mechanisms of miRNA packaging may protect 101 
circulating miRNAs from degradation. Their highly extracellular stability together with their 102 
often tissue-specific expression patterns and their feasible measurability by current techniques 103 
makes circulating miRNAs highly attractive as biomarkers in biomedical research.  104 
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Several recent studies have investigated circulating miRNAs in patients with severe chronic 106 
kidney disease (27, 29), end stage renal disease (10, 39), or acute kidney injury (19, 24, 38). 107 
However, little is known about the association between circulating miRNAs and kidney 108 
function in patients at high cardiovascular risk, such as coronary patients.  109 
 110 
Therefore, we (i) determined the expression of 50 miRNAs, previously associated in the 111 
literature with kidney function or kidney disease in a set of plasma samples obtained from 112 
coronary angiography patients, (ii) identified those circulating miRNAs putatively related to 113 
kidney function and (iii) validated their diagnostic value in a further independent cohort of 114 






Study subjects 121 
Patients were selected from a Caucasian patient cohort totally comprising 1048 subjects 122 
referred to elective coronary angiography for the evaluation of established or suspected stable 123 
coronary artery disease (CAD) at the academic teaching hospital Feldkirch.  124 
The Ethics Committee of the University of Innsbruck approved the present study and written 125 
informed consent was given by all participants. Detailed information on the recruitment 126 
protocol and the determination of subjects characteristic has been described previously (26, 127 
32). In brief, venous blood samples were collected after an overnight fast of 12 h before 128 
angiography was performed. Height and weight were recorded, and body mass index (BMI) 129 
was calculated as body weight (kg)/height2 (m2). Hypertension was defined according to the 130 
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and 131 
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Treatment of High Blood Pressure (34) and type 2 diabetes mellitus (T2DM) was diagnosed 132 
according to American Diabetes Association (ADA) guidelines (2). Coronary angiography 133 
was performed with the Judkin's technique and the severity of stenosis was assessed by visual 134 
inspection by a team of two investigators, who were blinded to serologic assays as described 135 
previously (8). Estimated glomerular filtration rate (eGFR) was assessed by the ‘Mayo Clinic 136 
Quadratic’ (MQ) equation, if not otherwise noted. The MQ equation is based on sex, age, and 137 
serum creatinine and has been shown to give an accurate estimate of the glomerular filtration 138 
rate in patients with nearly normal renal function (33). Additionally, the ‘Chronic Kidney 139 
Disease Epidemiology Collaboration’ (CKD-EPI) equitation (17) was used to estimate 140 
glomerular filtration rate. Renal function was classified as normal kidney function in subjects 141 
with eGFR ≥90 mL/min/1.73 m2, mild impairment of kidney function in subjects with eGFR 142 
60-89 mL/min/1.73 m2, and chronic kidney disease in subjects with eGFR<60 ml/min/1.73m2 143 
(28). Urinary albumin excretion was expressed as the albumin/creatinine concentration ratio 144 
(ACR) in a random fresh morning urine specimen.  145 
 146 
Study design 147 
In a first pre-selecting step, a candidate miRNA panel consisting of 50 miRNAs previously 148 
associated in the literature with renal function and/or involved in the development and 149 
progression of kidney disease (Supplemental Table S1) was analyzed in 60 plasma samples 150 
obtained from patients with angiographically proven CAD to identify those miRNAs, which 151 
were sufficiently detectable in plasma. MiRNAs sufficiently detectable in plasma were 152 
defined as miRNAs showing raw ct-values <39 cycles in at least 70% of samples. MiRNAs 153 
miR-24-3p, miR-92a-3p, and miR-222-3p were selected as endogenous reference miRNAs 154 
based on previously performed experiments at our institution and proposed as normalizers in 155 
other reports (22, 35, 40).  156 
 157 
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MiRNAs being detectable below selected cutoff were analyzed in 60 additional coronary 158 
patients. In doing so, a final discovery set was generated totally comprising 120 patients, 159 
which was used to evaluate the association between selected miRNAs and renal function.  160 
 161 
MiRNAs providing significant association with renal function after multiple testing correction 162 
in the discovery study cohort were re-tested in further 318 patients randomly selected out of 163 
remaining subjects referred to coronary angiography. Finally, the association of selected 164 
miRNAs with kidney function was assessed in the two combined patient cohorts totally 165 
including 438 coronary angiography patients.  166 
 167 
Prospective study 168 
Kidney function was re-assessed based on creatinine values obtained at a follow-up visit after 169 
3.6±1.2 years. 170 
 171 
miRNA analysis 172 
RNA was isolated from 0.2 ml plasma using the ‘miRNeasy Mini Kit’ (Qiagen, Hilden, 173 
Germany) according the manufactures protocol for the purification of small RNAs from 174 
plasma. Isolated miRNAs were reverse transcribed using ‘Universal cDNA Synthesis Kit’ 175 
(Exiqon, Vedbaeck, Denmark) according to the manufactures instructions for plasma derived 176 
miRNAs. Subsequently, quantitative real-time PCR was performed using ‘Universal SYBR 177 
Green master mix’ (Exiqon) and miRNA specific LNA™ PCR primer or ‘Pick-&-Mix 178 
microRNA PCR Panel’ plates (Exiqon) in a 10µl volume on a LightCycler® 480 Real-Time 179 
PCR System (Roche Diagnostics, Vienna, Austria). Ct values of each candidate miRNA were 180 
recorded and normalized by the global mean of all miRNAs (pre-selecting study) or by the 181 
mean expression of the selected reference miRNAs miR-24-3p, miR-92a-3p, and miR-222-3p 182 
(discovery and validation study). 183 




Statistical analysis 185 
MiRNA expression levels are given as 2−ΔCt values, such that increased values reflect 186 
increased miRNA concentration. Normal distribution was assessed using Kolmogorov-187 
Smirnov and Shapiro-Wilk test, respectively, showing that miRNA expression levels were not 188 
normally distributed. Association between miRNAs and continuous clinical/laboratory 189 
parameters were explored using non-parametric Spearman’s rank correlation tests. Benjamini 190 
and Hochberg false discovery rate correction was used for correcting multiple testing (4). In 191 
addition, analysis of covariance models (ANCOVA) were built using a general linear model 192 
approach. Statistically significant differences between miRNAs and categorical variables 193 
were determined by the Kruskal-Wallis test and the Mann–Whitney U test, respectively. P-194 
values <0.05 were considered significant. Statistical analyses were performed with SPSS 25.0 195 






Patients’ characteristics  202 
Clinical and biochemical baseline characteristics of patients included in the discovery cohort, 203 
the validation cohort as well in the combined patient cohorts are given in table 1. Study 204 
cohorts showed a high proportion of patients with male sex, the metabolic syndrome, T2DM, 205 
hypertension, and significant coronary artery stenoses. The discovery cohort and the 206 
validation cohort showed similar eGFR values (p=0.791). Approximately 10% of patients 207 
showed eGFR values below 60 mL/min/1.73 m2. Consequently, most patients had normal 208 
kidney function. 209 




Evaluation of miRNAs levels in plasma samples 211 
A pre-selection study performed in 60 patients of the discovery study cohort showed that 12 212 
miRNAs out of 50 analysed candidate miRNAs showed raw ct-values ≥39 cycles in at least 213 
30% of samples and therefore were excluded from further investigations (Supplemental Table 214 
S1). Expression data of miRNAs either normalized by the global mean or by the mean 215 
expression of selected reference miRNAs miR-24-3p, miR-92a-3p, and miR-222-3p were 216 
highly correlated (mean correlation coefficient = 0.950). Furthermore, selected reference 217 
miRNAs were not associated with kidney function in the pre-selection set (all p-values 218 
>0.05). Therefore, miR-24-3p, miR-92a-3p, and miR-222-3p were found to be appropriate 219 
endogenous reference miRNAs and were used as references in the further study. In a next 220 
step, miRNAs with sufficient expression were analysed in additional 60 patients generating a 221 
discovery cohort totally comprising 120 patients. Plasma levels of individual miRNAs are 222 
shown in Supplemental Fig. S1. MiRNA-451a showed highest expression levels, followed by 223 
miR-16-5p. 224 
 225 
Associations between miRNAs and eGFR in the discovery and validation cohort 226 
Associations between individual candidate miRNAs and eGFR are given in Supplemental 227 
Table S2. Out of 38 miRNAs of the discovery set, 15 miRNAs were significantly associated 228 
with eGFR at a nominal level of significance. Associations of seven out of these miRNAs 229 
(miR-16-5p, miR-19b-3p, miR-20a-5p, miR-25-3p, miR-106b-5p, miR-320a, and miR-451a) 230 
with eGFR remained significant after multiple testing correction via false discovery rate 231 
(FDR) estimation. To verify obtained results, miRNAs with significant FDR and additionally 232 
miR-320b showing borderline FDR significance with eGFR were further analysed in the 233 
validation cohort (n=318). Table 2 shows correlation between these miRNAs and eGFR in the 234 
validation study. MiRNAs miR-106b-5p, miR-16-5p, miR-19b-3p, miR-20a-5p, miR-25-3p, 235 
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and miR-451a, but not miR-320a and miR-320b, proved to be significantly associated with 236 
eGFR also in the validation study cohort.  237 
 238 
Associations between identified renal miRNAs and kidney function in the total study cohort 239 
The association of identified renal miRNAs with traits of kidney function was further 240 
investigated in the combined study cohorts totally comprising 438 subjects. As to be expected, 241 
the associations between identified renal miRNAs and eGFR were significant also in the total 242 
study cohort. MiRNAs also remained significantly associated with kidney function 243 
alternatively using the CKD-EPI equitation (17) instead of the Mayo Clinic Quadratic 244 
equation to estimate glomerular filtration rate (Supplemental Table S3). Identified renal 245 
miRNAs were able to significantly discriminate between normal and mildly impaired 246 
glomerular filtration rate (figure 1). Furthermore, a significant association between identified 247 
renal miRNAs and eGFR was proved by ANCOVA adjusting for age, gender, T2DM, 248 
hypertension, and ACR (Supplemental Table S4).  249 
 250 
Spearman correlation analysis revealed a high correlation of identified renal miRNAs with 251 
each other (Supplemental Table S5). In ANCOVA adjusting for each identified renal miRNA, 252 
only associations between the miR-19b-3p, miR-106b-5p and miR-451a with eGFR remained 253 
significant (Supplemental Table S6). 254 
 255 
To further elucidate the impact of the identified renal miRNAs on kidney function, the 256 
association between identified renal miRNAs and parameters, which were associated with 257 
kidney function, was assessed. Results of correlation analysis are given in table 3. The 258 
identified renal miRNAs were significantly associated with age and established renal markers 259 
including ACR, urea, and FGF23 serum levels. However, after adjustment for eGFR in 260 
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ANCOVA, the associations between miRNAs and these variables did not remain significant 261 
(all p-values >0.05). 262 
 263 
Associations between identified renal miRNAs and future kidney function  264 
Creatinine serum concentrations and eGFR assessments were available from 271 subjects out 265 
of the 438 initially included patients from a follow-up visit after 3.6±1.2 years. All baseline 266 





In the present work we report a strong correlation of the six plasma-derived miRNAs miR-16-272 
5p, miR-19b-3p, miR-20a-5p, miR-25-3p, miR-106b-5p, and miR-451a with kidney function 273 
in coronary patients. Our findings are based on a multi-step strategy, including a discovery 274 
study to identify circulating miRNAs significantly associated with kidney function as well as 275 
an independent validation study to verify obtained results. Identified renal miRNAs were even 276 
able to significantly discriminate between normal and mildly impaired eGFR. 277 
 278 
Our observations are in line with previous studies also demonstrating a significant reduction 279 
of circulating miRNAs in patients with CKD. In this regard, Neal et al. (29) showed that in 280 
patients with severe chronic kidney disease, circulating levels of total and specific miRNAs, 281 
including miR-16-5p, are reduced in comparison to patients with mild renal impairment or 282 
normal renal function. Furthermore, Lee et al. (16) reported that circulating miR-20a-5p and 283 
miR-106b-5p were significantly lower in CKD patients than in healthy subjects. Notably, the 284 
association between plasma-derived miR-19b-3p, miR-25-3p, and miR-451a and kidney 285 
function in humans, as described in our study, is new. 286 




That said, it remains unclear whether the identified circulating renal miRNAs are directly 288 
involved in kidney function or are a result of impaired kidney function. MiR-20a-5p together 289 
with miR-19b-3p and several other miRNAs belongs to the miR-17~92 cluster, which is 290 
highly conserved in vertebrates. MiR-106b-5p and miR-25-3p are members of the 291 
miR106b~25 cluster, a paralog of the miR-17~92 cluster originated by gene duplication and 292 
deletion events during vertebrate evolution (7). Both clusters are essential for development 293 
and homeostasis promoting cell division and resistance to apoptosis (7). Apoptosis promotes 294 
loss of renal epithelial cells that characterizes acute and chronic kidney disease. Therefore, it 295 
may be hypothesized that the observed reduced circulating levels of miRNAs miR-19b-3p, 296 
miR-20a-5p, miR-25-3p, and miR-106b-5p as members of the miR-17~92 cluster family 297 
reflect an increase in apoptotic processes in the kidneys accelerating renal dysfunction. The 298 
supposed impact of the 17~92 cluster family on renal function is supported by animal studies. 299 
In this regard, Marrone et al. showed that the miR-17~92 cluster is essential in renal 300 
development and that its loss leads to the development of renal disease in mice (23). 301 
However, the individual mechanisms by which low plasma levels of members of the miR-302 
17~92 cluster family contribute to renal function remain to be elucidated. 303 
 304 
Interestingly, renal miRNAs of the miR-17~92 cluster family were not only highly correlated 305 
to each other but also to miR-16-5p and miR-451a, which belong to the miR-15~16 cluster 306 
and the miR-144~451 cluster, respectively. The high correlation between circulating miR-16-307 
5p and miR-19b-3p has also been observed by Zhang et al., linking low levels of plasma-308 
derived miR-16-5p and miR-19b-3p to gastric cancer (43). In this regard, the association 309 
between miR-16-5p and renal function was no longer significant after adjusting for other 310 
identified renal miRNA. Therefore, the significant association between circulating miR-16-5p 311 
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and eGFR observed in our study and by others (29) appears to be mediated by other miRNAs, 312 
closely correlated to miR-16-5p, such as miR-19b-3p.  313 
 314 
However, a direct impact of circulating miR-451-5p on kidney function cannot be excluded. 315 
Animal studies showed that miR-451-5p is downregulated in diabetic kidney disease 316 
suggesting a protective role of miR-451-5p in kidney tissue (25, 44). It has been shown that 317 
overexpression of miR-451-5p inhibits glomerular mesangial cell hypertrophy (44), a key 318 
event occurring at a very early stage of diabetic nephropathy. That said, in the present study 319 
the association between circulating miR-451-5p and kidney function was independent from 320 
the presence of T2DM.  321 
 322 
Notably, miR-16-5p together with miR-451-5p showed highest expression levels among the 323 
investigated candidate miRNA panel (Supplemental Fig. S1), indicating that miR-16-5p and 324 
miR-451-5p account for a significant proportion of total circulating miRNA. Low levels of 325 
miR-16-5p or miR-451-5p may therefore reflect reduced levels of total circulating miRNA, 326 
which by itself has been associated with reduced kidney function (29). However, the 327 
biological background behind the association between reduced miRNA levels and reduced 328 
kidney function is still unclear. In this context, it has been shown that subjects with renal 329 
dysfunction show enhanced levels of RNases (12, 14) probably leading to increased 330 
degradation and, consequently, reduced levels of circulating miRNAs. That said, this 331 
hypothesis has been rejected by several authors due to the given protection of circulating 332 
miRNAs from degradation by different mechanisms of miRNA packaging such as the 333 
incorporation of miRNAs into vesicles or the formation of protein-miRNA complexes (11, 334 
29). Also, the question remains, why some plasma miRNAs are associated with eGFR while 335 
others are not.  336 
 337 
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Evidence suggests that different miRNA transport forms are associated with distinct miRNA 338 
signatures (6). Certain miRNAs were mainly detected in microvesicles, whereas others were 339 
associated with the RNA binding protein Argonaute 2 (3), which is part of the RNA-induced 340 
silencing complex. It may be hypothesized that the kind of extracellular miRNA stabilization 341 
contributes to our observation that a specific signature of abundant plasma miRNAs is 342 
associated with eGFR, while other common miRNAs (such as miR-223-3p or miR 486-5p) 343 
are not. However, sub-classes of miRNA carriers were not determined in our study and, 344 
therefore, any conclusions in that regard remain speculative. 345 
 346 
Our study has strengths and limitations. One strength of our study is the two-step strategy to 347 
identify circulating miRNAs associated with renal function. Significant associations between 348 
six miRNAs and eGFR found in a discovery study could be confirmed in a further 349 
independent study cohort. However, limited sample size of the discovery study might have 350 
reduced the chance of detecting true associations between other candidate miRNAs and 351 
kidney function. Another limitation is that GFR was not measured directly, but was estimated 352 
based on serum creatinine levels by the Mayo Clinic Quadratic equation. Notably, the Mayo 353 
Clinic Quadratic equation has been shown to give an accurate estimate of GFR in patients 354 
with nearly normal renal function (33), which was present in the majority our patients. Results 355 
could also be reproduced employing the more frequently used CKD-EPI equation. Creatinine 356 
values used to estimate GFR were based on a single measurement. Consequently, a non-357 
steady state of kidney function indicated by varying creatinine levels over time cannot be 358 
excluded for all of our patients. However, per study design patients included in our study were 359 
not acutely ill or hospitalized. Therefore, a steady state of kidney function making eGFR 360 
interpretable appears likely at least in most of our patients. Moreover, identified renal 361 
miRNAs were significantly linked with eGFR assessments based on creatinine values 362 
determined nearly four years after baseline examination confirming their association with 363 
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kidney function. Our study participants were a selected group as all of them were referred to 364 
coronary angiography for the evaluation of CAD. That said, due to the close correlation 365 
between even mild-to-moderate deterioration of kidney function and morbidity or mortality in 366 
cardiovascular risk patients, the coronary angiography patients we chose to investigate are of 367 
particular clinical interest. The impact of identified renal miRNAs on the incidence of future 368 
events has to be investigated in prospective studies. 369 
 370 
In conclusion, our study showed that decreased circulating levels of miR-16-5p, miR-19b-3p, 371 
miR-20a-5p, miR-25-3p, miR-106b-5p, and miR-451a are significantly linked to reduced 372 
kidney function in coronary angiography patients. Their close correlation to each other as well 373 
as to kidney function should be considered in future studies. Further studies are needed to 374 
clarify the pathophysiological background behind the observed association between reduced 375 
levels of identified circulating renal miRNAs and kidney dysfunction. 376 
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FIGURE LEGENDS 535 
 536 
Figure 1: Associations between identified renal miRNAs and kidney function evaluated 537 
in the total study cohort (n=438). Figure 1 shows relative plasma expression levels of miR-538 
16-5p (A), miR-19b-3p (B), miR-20a-5p (C), miR-25-3p (D), miR-106b-5p (E), and miR-539 
451a (F) in patients with normal kidney function (eGFR ≥90 mL/min/1.73 m2), mild 540 
impairment of kidney function (eGFR <90-60 mL/min/1.73 m2), and kidney disease (eGFR 541 
<60 mL/min/1.73 m2). Expression levels are given as 2−ΔCt values (median and interquartile 542 
range), such that increased y-axis values reflect increased miRNA concentration; Ct values 543 
were normalized by the mean expression of miR-24-3p, miR-92a-3p, and miR-222-3p. 544 
Statistically significant differences were determined by the Kruskal-Wallis test and the Mann–545 
Whitney U test, respectively. P-values between stages were given either as n.s. (non 546 
significant): P ≥ 0.05, *: P < 0.05, **: P < 0.01, or ***: P < 0.001.  547 
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Total cohort  
n=438 
Age (years) 67.5 ± 9.8 67.1 ± 9.8 67.2 ± 9.6 
Male gender, n (%) 67 (55.8) 173 (54.4) 240 (54.8) 
Body mass index (kg/m2) 28.7 ± 5.0 28.0 ± 4.6 28.2 ± 4.7 
Metabolic syndrome, n (%) 65 (54.2) 135 (42.5) 200 (45.7) 
Type 2 diabetes, n (%) 64 (55.3) 131 (42.2) 195 (44.5) 
Hypertension, n (%) 92 (67.7) 247 (77.7) 339 (77.4) 
History of smoking, n (%) 73 (60.8) 173 (54.4) 246 (56.2) 
Significant stenoses, n (%) 81 (67.5) 164 (51.6) 245 (55.9) 
Total cholesterol (mg/dl) 196.1 ± 41.5 196.0 ± 47.6 196.1 ± 46.0 
HDL-cholesterol (mg/dl) 56.0 ± 15.3 58.6 ± 17.4 57.9 ± 16.9 
Triglycerides (mg/dl) 143.5 ± 105.6 135.4 ± 78.7 137.6 ± 86.9 
Statin use, n (%) 60 (50.0) 161 (50.6) 221 (50.5) 
eGFR (ml/min/1.73m2) 91.8 ± 22.2 91.1 ± 19.8 91.3 ± 20.5 
eGFR 89 – 60 ml/min/1.73m2, n (%) 42 (35.0) 124 (38.8) 165 (37.8) 
eGFR < 60 ml/min/1.73m2, n (%) 12 (10.0) 28 (8.8) 40 (9.2) 
ACR (mg/g) 181.7 ± 429.7 71.9 ± 205.8 100.8 ± 285.8 
 
eGFR, estimated glomerular filtration rate; ACR albumin to creatinine concentration ratio. 
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Table 2: Associations of renal miRNAs identified in the discovery study with eGFR in 
the validation study  
   rho p-value 
miR-16-5p 0.239 <0.001 
miR-19b-3p 0.301 <0.001 
miR-20a-5p 0.292 <0.001 
miR-25-3p 0.196 <0.001 
miR-106b-5p   0.343 <0.001 
miR-320a -0.054 0.338 
miR-320b -0.015 0.788 
miR-451a 0.361 <0.001 
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Table 3: Associations between identified renal miRNAs and anthropometrics and laboratory parameters 
microRNA 
miR-16-5p miR-19b-3p miR-20a-5p miR-25-3p  miR-106b-5p miR-451a 
rho p-value rho p-value rho p-value rho p-value  rho p-value rho p-value 
Age -0.115 0.017 -0.115 0.017 -0.155 0.001 -0.130 0.006  -0.175 <0.001 -0.202 <0.001 
BMI -0.018 0.701   -0.046 0.341   -0.040 0.408   0.050 0.299   -0.051 0.290  0.012 0.797 
Glucose 0.069 0.148  0.032 0.507  0.031 0.513  0.116 0.015  -0.031 0.513 0.122 0.011 
HbA1c 0.044 0.361  -0.016 0.747  0.027 0.575  0.099 0.038  -0.019 0.691 0.086 0.071 
SBP (mm Hg) -0.036 0.452  -0.088 0.069  -0.069 0.151  -0.013 0.787  -0.056 0.244 -0.042 0.379 
DBP (mm Hg) -0.038 0.428  -0.102 0.034  -0.028 0.561  -0.005 0.918  -0.029 0.551 -0.007 0.881 
ACR -0.215 <0.001 -0.153 0.008 -0.172 0.003 -0.137 0.017  -0.195 0.001 -0.129 0.024 
Urinary albumin -0.071 0.149  -0.061 0.213  -0.102 0.039  -0.016 0.744  -0.116 0.018 -0.011 0.826 
Serum urea -0.081 0.089 -0.147 0.002 -0.161 0.001 -0.070 0.144  -0.214 <0.001 -0.154 0.001 
Serum 
uromodulin 0.009 0.879  -0.012 0.838  0.091 0.114  -0.028 0.627  0.114 0.048 0.037 0.521 
PTH -0.091 0.067  -0.096 0.055  -0.130 0.009  -0.076 0.126  -0.096 0.053 -0.092 0.064 
FGF23 -0.096 0.071  -0.180 0.001  -0.137 0.010  0.008 0.886  -0.158 0.003 -0.139 0.009 
Klotho 0.014 0.780  0.078 0.125  0.014 0.786  -0.066 0.196  0.041 0.424 0.043 0.395 
 
Associations of identified renal miRNAs with anthropometrics and laboratory parameters were evaluated in the total study cohort (n=438). 
Statistically significant differences were determined by the Spearman's rho correlation test. Significant associations are indicated in bold. BMI, body 
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mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACR, albumin-to-creatinine ratio; PTH, Parathyroid hormone; FGF23, 
Fibroblast growth factor 23. 
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